Tranexamic acid in cardiac surgery: Are low doses enough?

• Published in: Revista española de anestesiología y reanimación (English ed.) Vol. 68; no. 10; p. 576
• Main Authors: Peña Borras, J J, Pajares Moncho, A, Puig, J, Mateo Rodríguez, E, López Forte, C, Peña Pérez, L, Moreno Pachón, J, Gabaldón Conejos, T, Pérez Artacho, J, Ferrer Gómez, C, Férez Martí, A, López Cantero, M, de Andrés Ibáñez, J
• Format: Journal Article
• Language: English
• Published: Spain 01.12.2021
• Subjects: Antifibrinolytic Agents - therapeutic use; Cardiac Surgical Procedures; Humans; Medicin och hälsovetenskap; Postoperative Hemorrhage - prevention & control; Prospective Studies; Tranexamic Acid - therapeutic use; Sangrado; Transfusion; Transfusión; Fibrinólisis; Tranexamic acid; Ácido tranexámico; Cardiac surgery; Convulsiones; Convulsions; Cirugía cardíaca; Fibrinolysis; Bleeding
• ISSN: 2341-1929; 2341-1929
• DOI: 10.1016/j.redar.2021.02.008

Tranexamic acid is used to prevent hyperfibrinolysis and reduce postoperative bleeding and blood transfusions in on-pump cardiac surgery. We evaluate the efficacy of low or high dose tranexamic acid in a prospective cohort study conducted in Valencia. A total of 427 patients were recruited between January 2019 and January 2020, 207 in the Hospital General Universitario (low dose [LD]) and 220 in the Hospital Universitario y Politécnico La Fe (high dose [HD] and intermediate dose [ID]). We recorded the presence of hyperfibrinolysis on rotational thromboelastometry, intra- and postoperative administration of blood products, chest tube output within the first 12 h, and incidence of convulsions. Univariate and multivariate comparisons were performed. Univariate analysis of all categories was performed after propensity score matching between LD and HD and between LD and ID. There were no statistically significant differences in: appearance of hyperfibrinolysis, administration of blood products, postoperative chest tube output within the first 12 h, or occurrence of convulsions. Group LD received less fibrinogen than group HD (P = .014) and ID (P = .040) but more fresh frozen plasma than group ID (P = .0002). Administration of low-dose tranexamic acid is as effective as higher doses in hyperfibrinolysis prophylaxis and the prevention of postoperative bleeding in cardiac surgery.